Clinical Trial Update: Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial comparing sacituzumab govitecan with physician's choice in HR+/HER2- metastatic breast cancer after endocrine therapy is currently acti…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Hormone Receptor-positive Breast Cancer

Drugs mentioned

• Sacituzumab Govitecan (sacituzumab govitecan)

Snippet

Sponsor: Gilead Sciences | Conditions: Locally Advanced or Unresectable Metastatic Breast Cancer, Stage IV Breast Cancer | Phase 3 | Status: ACTIVE_NOT_RECRUITING